Skip to main content

10-12-2019 | Haematology | Video

ASH 2019 | Dasatinib superior to imatinib in paediatric Philadelphia chromosome-positive ALL

Ching-Hon Pui discusses phase 3 findings showing improved survival with dasatinib versus imatinib given alongside intensive chemotherapy for the treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukaemia (3:47).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits